The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case-control study.
COVID-19
Convalescent plasma
Mortality
Severe COVID-19
Journal
Annals of clinical microbiology and antimicrobials
ISSN: 1476-0711
Titre abrégé: Ann Clin Microbiol Antimicrob
Pays: England
ID NLM: 101152152
Informations de publication
Date de publication:
19 Nov 2022
19 Nov 2022
Historique:
received:
19
08
2022
accepted:
08
11
2022
entrez:
19
11
2022
pubmed:
20
11
2022
medline:
23
11
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) causes life-threatening pneumonia. Convalescent plasma therapy (CPT) is expected to be the effective COVID-19 treatment for passive immunity. The high neutralizing antibodies titer of CPT is needed to prove the benefit in early developed severe COVID-19. This case-control study evaluated transfusion efficacy and adverse events with high-titer (≥ 1:320) COVID-19 convalescent plasma compared with standard care alone in severe COVID-19 pneumonia. Among 107 severe COVID-19 patients, 55 received CPT plus standard care, and 52 received standard care alone. All-cause mortality was 15.3% in the CPT group compared with 85.4% in the standard care group (p < 0.001). Univariate and multivariate analyses revealed reduced mortality with CPT (HR 0.14; 95% CI 0.07-0.31; p < 0.001 and HR 0.26; 95% CI 0.08-0.79; p = 0.018, respectively). CPT resulted in decreased use of mechanical ventilation, duration of supplemental oxygen, and high-flow oxygen requirement. Clinical and radiological outcomes improved. Immediate high neutralizing antibody titer CPT is safe and reduces mortality in early developed severe COVID-19 patients. The benefit of CPT in the early course of illness is challenging and requires additional study. Trial registration Thai clinical trials registry (TCTR) no. 20220101003.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (COVID-19) causes life-threatening pneumonia. Convalescent plasma therapy (CPT) is expected to be the effective COVID-19 treatment for passive immunity. The high neutralizing antibodies titer of CPT is needed to prove the benefit in early developed severe COVID-19.
OBJECTIVE
OBJECTIVE
This case-control study evaluated transfusion efficacy and adverse events with high-titer (≥ 1:320) COVID-19 convalescent plasma compared with standard care alone in severe COVID-19 pneumonia.
RESULTS
RESULTS
Among 107 severe COVID-19 patients, 55 received CPT plus standard care, and 52 received standard care alone. All-cause mortality was 15.3% in the CPT group compared with 85.4% in the standard care group (p < 0.001). Univariate and multivariate analyses revealed reduced mortality with CPT (HR 0.14; 95% CI 0.07-0.31; p < 0.001 and HR 0.26; 95% CI 0.08-0.79; p = 0.018, respectively). CPT resulted in decreased use of mechanical ventilation, duration of supplemental oxygen, and high-flow oxygen requirement. Clinical and radiological outcomes improved.
CONCLUSIONS
CONCLUSIONS
Immediate high neutralizing antibody titer CPT is safe and reduces mortality in early developed severe COVID-19 patients. The benefit of CPT in the early course of illness is challenging and requires additional study. Trial registration Thai clinical trials registry (TCTR) no. 20220101003.
Identifiants
pubmed: 36403020
doi: 10.1186/s12941-022-00542-2
pii: 10.1186/s12941-022-00542-2
pmc: PMC9675119
doi:
Substances chimiques
Antibodies, Neutralizing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51Informations de copyright
© 2022. The Author(s).
Références
Mayo Clin Proc. 2020 Sep;95(9):1888-1897
pubmed: 32861333
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
JAMA. 2021 Nov 02;326(17):1690-1702
pubmed: 34606578
N Engl J Med. 2022 May 5;386(18):1700-1711
pubmed: 35353960
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489
Nat Med. 2021 Nov;27(11):2012-2024
pubmed: 34504336
Am J Pathol. 2020 Aug;190(8):1680-1690
pubmed: 32473109
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34473652
J Clin Invest. 2020 Sep 1;130(9):4791-4797
pubmed: 32525844
Clin Infect Dis. 2011 Feb 15;52(4):447-56
pubmed: 21248066
Nat Med. 2020 Nov;26(11):1708-1713
pubmed: 32934372
Infez Med. 2020 Sep 1;28(3):357-366
pubmed: 32920571
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Lancet. 2021 May 29;397(10289):2049-2059
pubmed: 34000257
Antimicrob Agents Chemother. 1994 Aug;38(8):1695-702
pubmed: 7985997
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
Ann Intern Med. 2006 Oct 17;145(8):599-609
pubmed: 16940336
Clin Infect Dis. 1995 Jul;21(1):150-61
pubmed: 7578724
Crit Care Med. 2010 Apr;38(4 Suppl):e66-73
pubmed: 20154602
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Nat Commun. 2021 May 27;12(1):3189
pubmed: 34045486
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 33974559
medRxiv. 2020 Aug 12;:
pubmed: 32817978